A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
KaliVir Immunotherapeutics
Sotio Biotech Inc.
Novartis
NeoTX Therapeutics Ltd.
CRISPR Therapeutics
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Incyte Corporation
Numab Therapeutics AG
NuCana plc
Medicenna Therapeutics, Inc.
Turnstone Biologics, Corp.
SOLTI Breast Cancer Research Group
Checkpoint Therapeutics, Inc.
University Hospital, Antwerp
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Pfizer
NGM Biopharmaceuticals, Inc
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Rain Oncology Inc
University of Florida
Western Sydney Local Health District
Jules Bordet Institute
Institut Bergonié
Xencor, Inc.
Incyte Corporation
Calithera Biosciences, Inc
MacroGenics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Emory University
Abramson Cancer Center at Penn Medicine
Emory University
Shenzhen BinDeBio Ltd.
Kantonsspital Winterthur KSW
Stanford University
Masonic Cancer Center, University of Minnesota
Novartis
Children's Oncology Group
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)